{"id":"W4388666126","doi":"10.1016/j.jtocrr.2023.100601","title":"Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90%","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Sanofi; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Internal medicine; Cohort; Oncology; PD-L1; Immunotherapy; Clinical endpoint; Chemotherapy; Population; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001857962,0.0001047787,0.0002122085,0.001177035,0.0002284145,0.0006432413,0.0003403844,0.0003874361,0.0009807224],"category_scores_gemma":[0.005780926,0.000119437,0.0002674351,0.001124586,0.0003411052,0.0007909265,0.0003570833,0.0002970675,0.0001929668],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008248377,"about_ca_system_score_gemma":0.0003889615,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001346068,"about_ca_topic_score_gemma":0.003052872,"domain_scores_codex":[0.9986081,0.0005686308,0.0002941377,0.0001836314,0.0002241735,0.0001213879],"domain_scores_gemma":[0.9926769,0.001816808,0.004587377,0.0001250643,0.0002926364,0.0005011233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002055406,0.0000329467,0.9967725,0.00002765876,0.00003509302,0.00007359916,0.00003712183,0.0001096605,0.00007724255,0.00002196646,0.00007674105,0.002529995],"study_design_scores_gemma":[0.00001708591,0.0002403428,0.9977769,0.00001758958,0.00002844637,0.0006909608,0.0001362461,0.0004643202,0.0001363963,0.0000552848,0.00042894,0.000007502154],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972878,0.001301201,0.00008969123,0.0001319388,0.000005656213,0.00001126221,0.0006777508,0.000002985596,0.0004917237],"genre_scores_gemma":[0.9988837,0.0003664367,0.0001370235,0.00003710922,0.00001702109,0.00001316012,0.0004936942,0.000001098767,0.00005075974],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001857962,"threshold_uncertainty_score":0.009826005,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.204960016965594,"score_gpt":0.4796957161427269,"score_spread":0.2747356991771329,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}